Related Experiment Video
Updated: Oct 29, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Healthcare system conversion to a biosimilar: Trials and tribulations
Simon W Lam1, Kevin Amoline1, Christopher Marcum1
1Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA.
Purpose:
While biologic medications have transformed the care and management of millions of patients, they are a large financial strain on the healthcare system. Biosimilar medications present a great opportunity to improve care affordability. However, despite streamlined approval processes and the potential for cost savings, the acceptance and adoption of biosimilars have been slow. This descriptive report illustrates the preparation for, challenges of, and execution of an enterprise-wide biosimilar conversion within a large healthcare system. The 3 phases of biosimilar conversion utilized at our institution included selection of a biosimilar, pharmacy and therapeutics (P&T) committee approval, and implementation.
Summary:
When selecting a biosimilar, clinical data, medication safety, cost, institutional cost savings, payer coverage, patient assistance programs, and additional patient services should be taken into consideration to ensure patient care is not affected. Understanding and endorsement of biosimilar use by physician leadership, care managers, and pharmacists are crucial before implementation. P&T committee approval with clear delineation of the patient population (naive vs experienced), disease states, and whether the biosimilar would be the preferred medication should be obtained. Transparent communication of clear expectations to patients and coordination with the information technology (IT), contracting, and supply chain departments are necessary before the go-live date. Contracting and IT implementations should ideally take potential changes in biosimilar adoption into consideration and have enough flexibility to account for these changes. Planned evaluations of patients' experiences with the change to the biosimilar should be incorporated as part of the implementation plan.
Conclusion:
The barriers to biosimilar adoption are plentiful. Careful planning, clear communication, and coordination with all affected disciplines can ensure successful biosimilar conversion.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
08:01Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Bioequivalence: Overview
Clinical Trials: Overview
Drug Biotransformation: Overview
Drug Biotransformation: Overview